In the context of hematologic malignancies, in vitro studies showed that azacytidine (a standard of care DNA hypomethylating agent used in the treatment of AML) and myelodysplastic syndrome and venetoclax (a B-cell lymphoma-2 inhibitor used in AML), induces the expression of other pro-phagocytic pathway components such as calreticulin and CD47 [54]. Here, CALR is linked to acute myeloid leukemia.